With Reference the captioned subject, Press Release / Media Release title Extract of Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31,2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Asarfi Hospital reported strong Q3 FY26 results with revenue at ₹46.06 crore, up about 40% from ₹32.89 crore in Q3 FY25. Profit after tax (PAT) nearly doubled to ₹5.48 crore from ₹2.72 crore, with EBITDA margin at 22% and PAT margin at 12%. For the nine months ended December 2025, revenue rose to ₹126.57 crore (vs ₹86.67 crore) and PAT jumped to ₹12.98 crore (vs ₹7.15 crore). Growth was led by higher patient volumes — IPD revenue up 42% YoY and OPD revenue up 37% YoY — along with better average revenue per occupied bed (ARPOB) of ₹24,293 in Super-Specialty and ₹43,240 in the Cancer unit. Q3 basic EPS rose to ₹2.79 from ₹1.38 a year earlier, while ROCE improved to 14% in FY25 from 9% in FY24.
Sharp profit growth and margin expansion signal strong operational momentum, likely positive for the stock, though the rise in debt-to-equity from 0.45x to 0.60x in FY25 suggests increased leverage worth monitoring.